Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Fulvestrant 65Letrozole 55Paclitaxel 54pembrolizumab 42Trastuzumab 42ribociclib 39Specimen Handling 36palbociclib 35Capecitabine 35Carboplatin 34Anastrozole 34Tamoxifen 32exemestane 31abemaciclib 31pertuzumab 29Cyclophosphamide 27Magnetic Resonance Spectroscopy 26trastuzumab deruxtecan 24Radiotherapy 22Surveys and Questionnaires 20Blood Specimen Collection 20olaparib 18Biopsy 18Standard of Care 17Docetaxel 17Taxes 15130-nm albumin-bound paclitaxel 15eribulin 14Methods 14Mastectomy, Segmental 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Adjuvants, Immunologic × 90 days × Clear all
NCT06130826 2026-06-03

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 1 Suspended
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡